Versant Venture Management, LLC

In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 7, 2024), Versant Venture Management, LLC reported 8 stock positions worth $77.3 million. Its top holding was Crispr Therapeutics (CRSP) at 34.8% of the portfolio, followed by Contineum Therapeutics Class A (CTNM, 20.9%) and Skye Bioscience (SKYE, 20.8%). Compared with Q1 2024, it opened 1 new position, added to 1 and reduced 3. The biggest buy was a new position in Contineum Therapeutics Class A (CTNM) and the biggest sale Adverum Biotechnologies (ADVM, shares −0%).

Most Recent 13F
Q2 2026
Location
San Francisco, CA
CIK
0001560009
Portfolio Value
$77.3M (Q2 2024)
SEC Filing
0000950123-24-007328 ↗ filed Aug 7, 2024

Holdings Value

0$50.0M$100.0M$150.0M$200.0M$250.0M Q1 2024: $103.1M Q1 2024 Q2 2024: $77.3M $77.3M Q2 2024 Q3 2024: $63.6M Q3 2024 Q4 2024: $86.7M Q4 2024 Q1 2025: $60.2M Q1 2025 Q2 2025: $82.1M Q2 2025 Q3 2025: $212.5M Q3 2025 Q4 2025: $151.1M Q4 2025 Q1 2026: $141.4M Q1 2026 Q2 2026: $162.6M Q2 2026

Holdings 8 stocks · $77.3M
CRSP Crispr Therapeutics AG 34.84% 498,558 $26.9M No change
CTNM Contineum Therapeutics Inc. Class A 20.92% 918,163 $16.2M New
SKYE Skye Bioscience Inc. 20.81% 2,007,704 $16.1M Add +0.0%
RPTX Repare Therapeutics Inc. 11.30% 2,646,657 $8.7M No change
ADVM Adverum Biotechnologies Inc. 4.50% 506,821 $3.5M Reduce 0.0%
PASG Passage Bio Inc. 4.14% 4,026,417 $3.2M Reduce -18.8%
GRITSTONE BIO INC 2.85% 3,561,150 $2.2M No change
ALGS Aligos Therapeutics Inc. 0.66% 1,457,937 $510K Reduce -37.2%

Portfolio Sells Q1 2024 → Q2 2024
ADVM Adverum Biotechnologies Inc. Reduce 0.0% 4.50% −2.45
PASG Passage Bio Inc. Reduce -18.8% 4.14% −2.36
ALGS Aligos Therapeutics Inc. Reduce -37.2% 0.66% −1.54

Portfolio Buys Q1 2024 → Q2 2024
CTNM Contineum Therapeutics Inc. Class A New 20.92% +20.92
SKYE Skye Bioscience Inc. Add +0.0% 20.81% −9.64

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 8$162.6MGLUE, IPSC, JBIO, LENZ, CTNM
Q1 2026 8$141.4MGLUE, IPSC, LENZ, JBIO, CTNM
Q4 2025 7$151.1MGLUE, LENZ, JBIO, CRSP, CTNM
Q3 2025 9$212.5MLENZ, GLUE, JBIO, CRSP, SKYE
Q2 2025 8$82.1MGLUE, CRSP, JBIO, SKYE, RPTX
Q1 2025 7$60.2MGLUE, CRSP, CTNM, SKYE, RPTX
Q4 2024 7$86.7MGLUE, CRSP, CTNM, SKYE, RPTX
Q3 2024 6$63.6MCRSP, CTNM, RPTX, SKYE, ADVM
Q2 2024 8$77.3MCRSP, CTNM, SKYE, RPTX, ADVM
Q1 2024 7$103.1MCRSP, SKYE, RPTX, GRITSTONE BIO INC, ADVM